Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGINTERVENTIONAL

Clinical Utility of a Genomic Predictor Test on the Management of Cardiorenal Complications of Type 2 Diabetes

New GENOmic Predictor for COmplications Risk in Type 2 DIAbetes

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

The goal of this pragmatic trial is to provide Real World Evidence (RWE) on the impact of the result of a polygenic risk prediction test of cardiorenal complications of T2D, so that more patients at high risk of these complications achieve over an 18 months period, recommended therapeutic targets. This will be demonstrated as a significant improvement in a composite value including HbA1c or systolic blood pressure (SBP) or albuminuria (UACR), or glomerular filtration rate (GFR) lowering. Researchers will compare the recommended therapeutic targets of uninformed and informed patients to see if the knowledge of the risk by the patients and their treating physicians improves achievement of these targets. Participants will: Have a saliva sampling to determine the genetic risk. Visit the clinic once every 3 months for checkups and tests Answer two questionnaires on quality of life.

Who May Be Eligible (Plain English)

Who May Qualify: - Adult patients with T2D of both sexes regardless of ethnicity, level of diabetes control and presence of complications. - Able to visit the study site 7 times - Able and willing to provide willing to sign a consent form to the clinical and PRS parts of the study. Who Should NOT Join This Trial: - Any condition that may impact participation in a real-world study according to the treating physician. - People with a high frailty index as no benefit of therapeutic intensification has been demonstrated in these diabetic patients. - People who refuse to be informed of their cardiorenal risk score. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Adult patients with T2D of both sexes regardless of ethnicity, level of diabetes control and presence of complications. * Able to visit the study site 7 times * Able and willing to provide informed consent to the clinical and PRS parts of the study. Exclusion Criteria: * Any condition that may impact participation in a real-world study according to the treating physician. * People with a high frailty index as no benefit of therapeutic intensification has been demonstrated in these diabetic patients. * People who refuse to be informed of their cardiorenal risk score.

Treatments Being Tested

DEVICE

Polygenic Risk Score

The Polygenic Risk Score (PRS) is a Class II software as a medical device (SaMD) that estimates a person's level of risk of developing a disease or associated complications before clinical signs appear. The device uses the genomic profile of the person in combination with some clinical data (i.e., age, sex, age of onset of diabetes) to compute this risk. This device further provides recommendations for personalized management of T2D for patients based on their risk score.

Locations (2)

CHUM
Montreal, Quebec, Canada
ELNA Medical
Montreal, Quebec, Canada